Kidney transplantation restored uncoupled bone turnover in end-stage renal disease

Clinical Nephrology

Volumn 78, Issue 1, 2012, Pages 10-16

  Kawarazaki, Hiroo ^a   Shibagaki, Yugo ^a   Kido, Ryo ^b   Nakajima, Ichiro ^c   Fuchinoue, Shohei ^c   Ando, Katsuyuki ^b   Fujita, Toshiro ^a   Fukagawa, Masafumi ^d   Teraoka, Satoshi ^c   Fukumoto, Seiji ^b  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone specific alkaline phosphatase; Dialysis duration; Hyperparathyroidism; Kidney transplantation; Type 1 collagen cross linked n telopeptides

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BASILIXIMAB; COLLAGEN TYPE 1; CORTICOSTEROID; CYCLOSPORIN; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; BIOLOGICAL MARKER; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; IMMUNOSUPPRESSIVE AGENT; PARATHYROID HORMONE; PEPTIDE; PTH PROTEIN, HUMAN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; ORGAN DONOR; OSSIFICATION; OSTEOLYSIS; RENAL REPLACEMENT THERAPY; BLOOD; BONE; BONE DEVELOPMENT; BONE REMODELING; CHRONIC KIDNEY FAILURE; DRUG EFFECT; JAPAN; LIVING DONOR; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; BONE REMODELING; BONE RESORPTION; COLLAGEN TYPE I; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LINEAR MODELS; LIVING DONORS; MALE; MIDDLE AGED; OSTEOGENESIS; PARATHYROID HORMONE; PEPTIDES; PROSPECTIVE STUDIES; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84864573691     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107348     Document Type: Article

References (24)

1. Abbott KC, Oglesby RJ, Hypolite IO, Kirk AD, Ko CW, Welch PG, Agodoa LY, Duncan WE. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001; 11: 450-457. doi:10.1016/S1047-2797(01)00226-5 PubMed.
2. Elder G. Pathophysiology and recent advances in the management of renal osteodystrophy. J Bone Miner Res. 2002; 17: 2094-2105. doi:10.1359/jbmr.2002.17.12.2094 PubMed.
3. Bellorin-Font E, Rojas E, Carlini RG, Suniaga O, Weisinger J. R. Bone remodeling after renal transplantation. Kidney Int. 2003; 63 (Suppl 85): S125-S128. doi:10.1046/j.1523-1755.63.s85.30.x.
4. Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol. 2000; 54: 218-226. PubMed.
5. Casez JP, Lippuner K, Horber FF, Montandon A, Jaeger P. Changes in bone mineral density over 18 months following kidney transplantation: the respective roles of prednisone and parathyroid hormone. Nephrol Dial Transplant. 2002; 17: 1318-1326. doi:10.1093/ndt/17.7.1318 PubMed.
6. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF. Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab. 2005; 90: 3970-3977. doi:10.1210/jc.2003-1703 PubMed.
7. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD; Fracture Intervention Trial Study Group. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004; 19: 1250-1258. doi:10.1359/JBMR.040512 PubMed.
8. Taylor AK, Lueken SA, Libanati C, Baylink DJ. Biochemical markers of bone turnover for the clinical assessment of bone metabolism. Rheum Dis Clin North Am. 1994; 20: 589-607. PubMed.
9. Berman E, Nicolaides M, Maki RG, Fleisher M, Chanel S, Scheu K, Wilson BA, Heller G, Sauter NP. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006; 354: 2006-2013. doi:10.1056/NEJMoa0 51140 PubMed.
10. Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 1999; 84: 2363-2368. doi:10.1210/jc.84.7.2363 PubMed.
11. Borstnar S, Erzen B, Gmeiner Stopar T, Kocjan T, Arnol M, Kandus A, Kovac D. Treatment of hyperparathyroidism with cinacalcet in kidney transplant recipients. Transplant Proc. 2010; 42: 4078-4082. doi:10.1016/j.transproceed.20 10.09. 059 PubMed.
12. Kovesdy CP, Molnar MZ, Czira ME, Rudas A, Ujszaszi A, Rosivall L, Szathmari M, Covic A, Keszei A, Beko G, Lakatos P, Kosa J, Mucsi I. Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin J Am Soc Nephrol. 2010; 5: 2297-2304. doi:10.2215/CJN.03520410 PubMed.
13. Westenfeld R, Schlieper G, Wöltje M, Gawlik A, Brandenburg V, Rutkowski P, Floege J, Jahnen-Dechent W, Ketteler M. Impact of sirolimus, tacrolimus and mycophenolate mofetil on osteoclastogenesis - implications for post-transplantation bone disease. Nephrol Dial Transplant. 2011 on line.
14. Withold W, Friedrich W, Degenhardt S. Serum bone alkaline phosphatase is superior to plasma levels of bone matrix proteins for assessment of bone metabolism in patients receiving renal transplants. Clin Chim Acta. 1997; 261: 105-115. doi:10.1016/S0009-8981(97)06519-4 PubMed.
15. Reinhardt W, Bartelworth H, Jockenhövel F, Schmidt-Gayk H, Witzke O, Wagner K, Heemann UW, Reinwein D, Philipp T, Mann K. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant. 1998; 13: 436-442. doi:10.1093/ndt/13.2.434 PubMed.
16. Hurst G, Alloway R, Hathaway D, Somerville T, Hughes T, Gaber A. Stabilization of bone mass after renal transplant with preemptive care. Transplant Proc. 1998; 30: 1327-1328. doi:10.1016/S0041-1345(98)00262-0 PubMed.
17. Westeel FP, Mazouz H, Ezaitouni F, Hottelart C, Ivan C, Fardellone P, Brazier M, El Esper I, Petit J, Achard JM, Pruna A, Fournier A. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation. Kidney Int. 2000; 58: 1788-1796. doi:10.1046/j.1523-1755.200 0. 003 41.x PubMed.
18. Malluche HH, Monier-Faugere MC, Wang G, Frazã O JM, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008; 69: 269-278. PubMed.
19. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology. 1988; 123: 2571-2577. doi:10.1210/endo-123-5-2571 PubMed.
20. Rojas E, Carlini RG, Clesca P, Arminio A, Suniaga O, De Elguezabal K, Weisinger JR, Hruska KA, Bellorin-Font E. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int. 2003; 63: 1915-1923. doi:10.1046/j.1523-175 5.2003.00938.x PubMed.
21. Weisinger JR, Carlini RG, Rojas E, Bellorin-Font E. Bone disease after renal transplantation. Clin J Am Soc Nephrol. 2006; 1: 1300-1313. doi:10.2215/CJN.01510506 PubMed.
22. Kawarazaki H, Shibagaki Y, Fukumoto S, Kido R, Ando K, Nakajima I, Fuchinoue S, Fujita T, Fukagawa M, Teraoka S. Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study. Ther Apher Dial. 2011; 15: 481-487. doi:10.1111/j.1744-9987.2011.00932.x PubMed.
23. Goto S, Fujii H, Hamada Y, Yoshiya K, Fukagawa M. Association between indoxyl sulfate and skeletal resistance in hemodialysis patients. Ther Apher Dial. 2010; 14: 417-423. doi:10.1111/j.1744-9987.2010.00813.x PubMed.
24. Yamada S, Inaba M, Kurajoh M, Shidara K, Imanishi Y, Ishimura E, Nishizawa Y. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol (Oxf). 2008; 69: 189-196. doi:10.1111/j.13 65-2265. 2008.0 3187.x PubMed.